Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
PHASEBIO 製藥（NASDAQ：PHAS-獲取評級）和高山免疫科學（NASDAQ：ALPN-獲得評級）都是小型醫療公司，但哪個是更好的投資？我們將根據兩家企業的風險，估值，機構所有權，分析師建議，收益，盈利能力和股息來比較兩家企業。
Institutional & Insider Ownership
機構和內幕所有權
49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Alpine Immune Sciences shares are held by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Comparatively, 54.7% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
百富醫藥的 49.0% 股份由機構投資者持有。相比之下，79.0％ 的高山免疫科學股份由機構投資者持有。9.9％ 的 PaseBio 製藥股份由內部人士持有。相比之下，54.7％ 的高山免疫科學股份由內部人士持有。強大的機構所有權表明，捐贈基金，大型資金經理和對沖基金認為股票將在長期內優於市場。
Profitability
盈利
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' net margins, return on equity and return on assets.
此表格比較了 PHASEBIO 製藥和阿爾派免疫科學的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| PhaseBio Pharmaceuticals | -12,572.13% | N/A | -174.38% |
| Alpine Immune Sciences | -169.82% | -47.34% | -23.12% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 康西生技製藥 | -12,572.13% | N/A | -174.38% |
| 高山免疫科學 | -169.82% | -47.34% | -23.12% |
Analyst Recommendations
分析師推薦
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PhaseBio Pharmaceuticals | 0 | 5 | 0 | 0 | 2.00 |
| Alpine Immune Sciences | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 康西生技製藥 | 0 | 5 | 0 | 0 | 2.00 |
| 高山免疫科學 | 0 | 0 | 3 | 0 | 3.00 |
PhaseBio Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 4,636.84%. Alpine Immune Sciences has a consensus target price of $15.67, suggesting a potential upside of 157.68%. Given PhaseBio Pharmaceuticals' higher probable upside, equities analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Alpine Immune Sciences.
菲西生技製藥目前的共識目標價為 4.50 美元，表明潛在的上行空間為 4,636.84％。高山免疫科學的共識目標價格為 15.67 美元，表明潛在的上行空間為 157.68％。鑑於 PhaseBio 藥業的可能上漲空間較高，股票分析師清楚地認為 PhaseBio 製藥比高山免疫科學更有利。
Risk and Volatility
風險及波動性
PhaseBio Pharmaceuticals has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
菲西比奧製藥的測試版為 2.87，表明其股票價格比標普 500 的波動性高 187%。相比之下，高山免疫科學的測試版為 1.5，這表明其股票價格比標普 500 高 50％ 的波動性。
Valuation & Earnings
估值及收益
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' gross revenue, earnings per share (EPS) and valuation.
此表格比較了 PhaseBio 製藥和高山免疫科學的總收入，每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PhaseBio Pharmaceuticals | $10.83 million | 0.44 | -$131.07 million | ($2.13) | -0.04 |
| Alpine Immune Sciences | $23.44 million | 7.89 | -$50.33 million | ($1.92) | -3.17 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 康西生技製藥 | 一百八十三萬元 | 0.44 | -13,107 百萬美元 | (二元十三元) | -0.04 |
| 高山免疫科學 | 二千三百四十四萬元 | 7.89 | -五億三千三百萬元 | (一元九二) | -3.17 |
Alpine Immune Sciences has higher revenue and earnings than PhaseBio Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
高山免疫科學具有比 PhaseBio 製藥更高的收入和收入。高山免疫科學與 PhaseBio 製藥相比以較低的價格盈利比率進行交易，這表明它目前在兩隻股票中價格更便宜。
Summary
摘要
Alpine Immune Sciences beats PhaseBio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
高山免疫科學在 10 個因素中，兩隻股票之間的 14 個因素中擊敗了 PhaseBio 製藥。
About PhaseBio Pharmaceuticals
關於菲西生醫藥
(Get Rating)
(取得評分)
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
PhaseBio 製藥公司是一家臨床階段的生物製藥公司，致力於心血管疾病的新型療法的開發和商業化。該公司的管道包括：苯妥昔單抗（PB2452），用於治療肺動脈高血壓高血壓的新型反轉劑，pemziviptadil（PB1046），用於治療肺動脈高血壓的每週一次血管活性腸肽受體激動劑，以及 PB6440，用於治療抗性高血壓的口服劑。該公司由阿舍托什·奇爾科蒂和粘土貝爾納丁索普在 2002 年 1 月成立，總部設在馬爾文, PA.
About Alpine Immune Sciences
關於高山免疫科學
(Get Rating)
(取得評分)
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
高山免疫科學, Inc. 是一家臨床階段生物製藥公司，致力於發現和開發基於蛋白質的免疫療法，用於治療癌症，自身免疫/炎症性疾病和其他疾病。其產品線包括用於治療自身免疫性和炎症性疾病的誘導性 T 細胞共生劑（ICOS）/分化 28（CD28）拮抗劑計劃的 ALPN-101；ALPN-202，用於治療癌症和自身免疫性疾病的有條件 CD28 共興劑和雙檢查點抑製劑；以及用於治療 B 細胞免疫性疾病和自身免疫性疾病的雙 B 細胞因子拮抗劑 ALPN-303。該公司與艾伯維愛爾蘭無限公司簽訂了合作協議，以開發 ALPN-101；和 Adaptimmune 治療有限公司開發下一代的矛 T 細胞產品。高山免疫科學公司成立於 2007 年，總部位於華盛頓州西雅圖。
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收有關 PhaseBio 藥品的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 PaseBio 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。